Literature DB >> 21477948

Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer.

Jeffrey R Olsen1, Clifford G Robinson, Issam El Naqa, Kimberly M Creach, Robert E Drzymala, Charles Bloch, Parag J Parikh, Jeffrey D Bradley.   

Abstract

PURPOSE: To compare the efficacy of three lung stereotactic body radiotherapy (SBRT) regimens in a large institutional cohort.
METHODS: Between 2004 and 2009, 130 patients underwent definitive lung cancer SBRT to a single lesion at the Mallinckrodt Institute of Radiology. We delivered 18 Gy × 3 fractions for peripheral tumors (n = 111) and either 9 Gy × 5 fractions (n = 8) or 10 Gy × 5 fractions (n = 11) for tumors that were central or near critical structures. Univariate and multivariate analysis of prognostic factors was performed using the Cox proportional hazard model.
RESULTS: Median follow-up was 11, 16, and 13 months for the 9 Gy × 5, 10 Gy × 5, and 18 Gy × 3 groups, respectively. Local control statistics for Years 1 and 2 were, respectively, 75% and 50% for 9 Gy × 5, 100% and 100% for 10 Gy × 5, and 99% and 91% for 18 Gy × 3. Median overall survival was 14 months, not reached, and 34 months for the 9 Gy × 5, 10 Gy × 5, and 18 Gy × 3 treatments, respectively. No difference in local control or overall survival was found between the 10 Gy × 5 and 18 Gy × 3 groups on log-rank test, but both groups had improved local control and overall survival compared with 9 Gy × 5. Treatment with 9 Gy × 5 was the only independent prognostic factor for reduced local control on multivariate analysis, and increasing age, increasing tumor volume, and poor performance status predicted independently for reduced overall survival.
CONCLUSION: Treatment regimens of 10 Gy × 5 and 18 Gy × 3 seem to be efficacious for lung cancer SBRT and provide superior local control and overall survival compared with 9 Gy × 5.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21477948     DOI: 10.1016/j.ijrobp.2011.01.038

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

1.  Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).

Authors:  Feras Oskan; Yvonne Dzierma; Stefan Wagenpfeil; Christian Rübe; Jochen Fleckenstein
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy.

Authors:  Traves D Crabtree; Varun Puri; Clifford Robinson; Jeffrey Bradley; Stephen Broderick; G Alexander Patterson; Jingxia Liu; Joanne F Musick; Jennifer M Bell; Michael Yang; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-02       Impact factor: 5.209

3.  Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity.

Authors:  Alessandro Testolin; Maria Silvia Favretto; Stefania Cora; Carlo Cavedon
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

Review 4.  Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Authors:  Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li
Journal:  Radiother Oncol       Date:  2016-11-18       Impact factor: 6.280

5.  Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.

Authors:  Stephanie Markovina; Fenghai Duan; Bradley S Snyder; Barry A Siegel; Mitchell Machtay; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-01       Impact factor: 7.038

6.  Asymmetric margin setting at the cranial and caudal sides in respiratory gated and non-gated stereotactic body radiotherapy for lung cancer.

Authors:  Yoshihiro Ueda; Shingo Oohira; Masaru Isono; Masayoshi Miyazaki; Teruki Teshima
Journal:  Br J Radiol       Date:  2015-12-23       Impact factor: 3.039

Review 7.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

8.  Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC.

Authors:  Sung Uk Lee; Sung Ho Moon; Kwan Ho Cho; Hong Ryull Pyo; Joo Young Kim; Dae Yong Kim; Tae Hyun Kim; Yang-Gun Suh; Yeon-Joo Kim
Journal:  Strahlenther Onkol       Date:  2016-06-09       Impact factor: 3.621

9.  Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer.

Authors:  Ernesto Maranzano; Lorena Draghini; Romina Rossi; Michelina Casale; Fabio Trippa
Journal:  J Radiosurg SBRT       Date:  2013

10.  Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.

Authors:  Cole R Steber; Ryan T Hughes; Michael H Soike; Travis Jacobson; Corbin A Helis; Joshua C Farris; Michael K Farris
Journal:  Clin Lung Cancer       Date:  2020-09-18       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.